{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T13:22:17Z","timestamp":1788355337770,"version":"build-2803163510"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Immune checkpoint inhibitors (ICIs) have transformed cancer care but can cause immune-related adverse events (irAEs) involving almost any organ system. Delayed recognition may permit reversible inflammation to progress to organ dysfunction, treatment interruption, prolonged immunosuppression, or death. Biomarker surveillance offers an objective complement to symptom assessment, yet no single marker is sufficiently accurate for universal prediction. This Mini Review examines the mechanistic basis and clinical evidence for nursing-led biomarker monitoring during ICI therapy. Targeted autoantibody, cytokine, or immune-cell assays may support selected clinical evaluations, whereas germline, T-cell receptor, and microbiome signatures remain investigational. Dynamic changes are generally more informative than isolated values, but interpretation is complicated by cancer burden, infection, concomitant treatment, and pre-existing disease. Nurses are positioned to connect serial laboratory trends with patient-reported symptoms, vital signs, treatment timing, and escalation pathways. Prospective studies are needed to validate multimarker panels and determine whether biomarker-informed nursing pathways reduce severe irAEs without unnecessary testing or interruption of effective immunotherapy.<\/jats:p>","DOI":"10.3389\/fmed.2026.1943642","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T13:08:50Z","timestamp":1788354530000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Toward nursing-integrated biomarker surveillance for immune-related adverse events during immune checkpoint inhibitor therapy"],"prefix":"10.3389","volume":"13","author":[{"given":"Jiafeng","family":"Jin","sequence":"first","affiliation":[{"name":"Department of Nursing, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liwen","family":"Zheng","sequence":"additional","affiliation":[{"name":"Geriatric ICU, Jiangsu Province Hospital","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yali","family":"Tian","sequence":"additional","affiliation":[{"name":"Geriatric ICU, Jiangsu Province Hospital","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minjuan","family":"Chu","sequence":"additional","affiliation":[{"name":"Geriatric ICU, Jiangsu Province Hospital","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beinuo","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Nursing, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"5309","DOI":"10.1016\/j.cell.2021.09.020","article-title":"Hallmarks of response, resistance, and toxicity to immune checkpoint blockade","volume":"184","author":"Morad","year":"2021","journal-title":"Cell"},{"key":"B2","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e002435","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for immunotherapy of cancer clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: eSMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.alit.2022.01.001","article-title":"Immune-related adverse events in various organs caused by immune checkpoint inhibitors","volume":"71","author":"Okiyama","year":"2022","journal-title":"Allergol Int"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1167975","DOI":"10.3389\/fimmu.2023.1167975","article-title":"Immune-related adverse events of immune checkpoint inhibitors: a review","volume":"14","author":"Yin","year":"2023","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1080\/25785826.2021.1976942","article-title":"Immunopathological basis of immune-related adverse events induced by immune checkpoint blockade therapy","volume":"45","author":"Kubo","year":"2022","journal-title":"Immunol Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.3390\/cancers15051629","article-title":"Predictive biomarkers for checkpoint inhibitor immune-related adverse events","volume":"15","author":"Les","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B9","doi-asserted-by":"publisher","first-page":"991433","DOI":"10.3389\/fimmu.2022.991433","article-title":"Checkpoint inhibitor immune-related adverse events: a focused review on autoantibodies and B cells as biomarkers, advancements and future possibilities","volume":"13","author":"Taylor","year":"2023","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e498","DOI":"10.1097\/RHU.0000000000001777","article-title":"Autoantibodies in patients with immune-related adverse events from checkpoint inhibitors: a systematic literature review","volume":"28","author":"Ghosh","year":"2022","journal-title":"J Clin Rheumatol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e004008","DOI":"10.1136\/jitc-2021-004008","article-title":"Lower baseline autoantibody levels are associated with immune-related adverse events from immune checkpoint inhibition","volume":"10","author":"Ghosh","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e003625","DOI":"10.1136\/jitc-2021-003625","article-title":"Germline biomarkers predict toxicity to anti-PD1\/PDL1 checkpoint therapy","volume":"10","author":"Weidhaas","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e007236","DOI":"10.1136\/jitc-2023-007236","article-title":"T-cell receptor beta variable gene polymorphism predicts immune-related adverse events during checkpoint blockade immunotherapy","volume":"11","author":"Stephen","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"756872","DOI":"10.3389\/fimmu.2021.756872","article-title":"Intestinal microbiome associated with immune-related adverse events for patients treated with anti-PD-1 inhibitors: a real-world study","volume":"12","author":"Liu","year":"2021","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e2200348119","DOI":"10.1073\/pnas.2200348119","article-title":"Immune checkpoint inhibitors unleash pathogenic immune responses against the microbiota","volume":"119","author":"Hu","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B16","doi-asserted-by":"publisher","first-page":"eabq4006","DOI":"10.1126\/scitranslmed.abq4006","article-title":"Microbiome alteration via fecal microbiota transplantation is effective for refractory immune checkpoint inhibitor-induced colitis","volume":"15","author":"Halsey","year":"2023","journal-title":"Sci Transl Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jjco\/hyad184","article-title":"Biomarkers for immune-related adverse events in cancer patients treated with immune checkpoint inhibitors","volume":"54","author":"Liang","year":"2024","journal-title":"Jpn J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/s41598-020-79397-6","article-title":"Continuous monitoring of neutrophils to lymphocytes ratio for estimating the onset, severity, and subsequent prognosis of immune related adverse events","volume":"11","author":"Matsukane","year":"2021","journal-title":"Sci Rep"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1111\/1759-7714.14063","article-title":"Association between pretreatment neutrophil-to-lymphocyte ratio and immune-related adverse events due to immune checkpoint inhibitors in patients with non-small cell lung cancer","volume":"12","author":"Fujimoto","year":"2021","journal-title":"Thorac Cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12865-024-00599-y","article-title":"Predictive biomarkers for immune-related adverse events in cancer patients treated with immune-checkpoint inhibitors","volume":"25","author":"Wang","year":"2024","journal-title":"BMC Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"21666","DOI":"10.1002\/cam4.6724","article-title":"Eosinophil may be a predictor of immune-related adverse events induced by different immune checkpoint inhibitor types: a retrospective multidisciplinary study","volume":"12","author":"Tasaki","year":"2023","journal-title":"Cancer Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"9029","DOI":"10.1038\/s41598-021-88307-3","article-title":"Association of blood biomarkers and autoimmunity with immune related adverse events in patients with cancer treated with immune checkpoint inhibitors","volume":"11","author":"Michailidou","year":"2021","journal-title":"Sci Rep"},{"key":"B23","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12885-025-15460-7","article-title":"Using routine blood tests to predict severe immune-related adverse events during immune checkpoint inhibitor treatment","volume":"26","author":"Acar","year":"2025","journal-title":"BMC Cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1002\/ehf2.14340","article-title":"Inflammatory biomarkers in assessing severity and prognosis of immune checkpoint inhibitor-associated cardiotoxicity","volume":"10","author":"Liang","year":"2023","journal-title":"ESC Heart Fail"},{"key":"B25","doi-asserted-by":"publisher","first-page":"100787","DOI":"10.1016\/j.esmoop.2023.100787","article-title":"Immune-related adverse events as potential surrogates of immune checkpoint inhibitors' Efficacy: a systematic review and meta-analysis of randomized studies","volume":"8","author":"Amoroso","year":"2023","journal-title":"ESMO Open"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1053\/j.gastro.2021.06.025","article-title":"Interferon-gamma-producing CD8 +\u2009tissue resident memory T cells are a targetable hallmark of immune checkpoint inhibitor-colitis","volume":"161","author":"Sasson","year":"2021","journal-title":"Gastroenterology"},{"key":"B27","doi-asserted-by":"publisher","first-page":"800879","DOI":"10.3389\/fimmu.2021.800879","article-title":"Immune checkpoint inhibitor-associated colitis: from mechanism to management","volume":"12","author":"Tang","year":"2021","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e009742","DOI":"10.1136\/jitc-2024-009742","article-title":"Systematic review of immune checkpoint inhibitor-related gastrointestinal, hepatobiliary, and pancreatic adverse events","volume":"12","author":"Shatila","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B29","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/PAP.0000000000000346","article-title":"Gastrointestinal and hepatobiliary immune-related adverse events: a histopathologic review","volume":"29","author":"Alruwaii","year":"2022","journal-title":"Adv Anat Pathol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-22-0689","article-title":"Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline","volume":"187","author":"Husebye","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1213225","DOI":"10.3389\/fendo.2023.1213225","article-title":"Real-world adherence to toxicity management guidelines for immune checkpoint inhibitor-induced diabetes mellitus","volume":"14","author":"Shen","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B32","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the EHA, ESTRO and IC-OS","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"B33","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1097\/JXX.0000000000000860","article-title":"A case study of myopericarditis due to immune checkpoint inhibitor therapy: proposed surveillance and management","volume":"35","author":"Kuhnly","year":"2023","journal-title":"J Am Assoc Nurse Pract"},{"key":"B34","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.jid.2021.06.040","article-title":"Immune checkpoint blockade and skin toxicity pathogenesis","volume":"142","author":"Ma","year":"2022","journal-title":"J Invest Dermatol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/CJI.0000000000000390","article-title":"Management and outcomes of hematological immune-related adverse events: systematic review and meta-analysis","volume":"45","author":"Wilson","year":"2022","journal-title":"J Immunother"},{"key":"B36","doi-asserted-by":"publisher","first-page":"100076","DOI":"10.1016\/j.apjon.2022.100076","article-title":"Exploring the educational needs for severe immune-related adverse events of PD-1\/PD-L1 inhibitors in advanced lung cancer: a single-center observational study","volume":"9","author":"Aso","year":"2022","journal-title":"Asia Pac J Oncol Nurs"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1200\/OP.21.00192","article-title":"Home-based management of patients with cancer experiencing treatment-induced toxicities with a nurse-led telephone triage: the NTT study","volume":"18","author":"Calvetti","year":"2022","journal-title":"JCO Oncol Pract"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e1631","DOI":"10.1200\/OP.20.00845","article-title":"Evaluation of a multidisciplinary immunotherapy toxicity monitoring program for patients receiving ipilimumab for metastatic melanoma","volume":"17","author":"Menjak","year":"2021","journal-title":"JCO Oncol Pract"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e224427","DOI":"10.1001\/jamanetworkopen.2022.4427","article-title":"Efficiency of electronic health record assessment of patient-reported outcomes after cancer immunotherapy: a randomized clinical trial","volume":"5","author":"Zhang","year":"2022","journal-title":"JAMA Netw Open"},{"key":"B40","doi-asserted-by":"publisher","first-page":"e2200185","DOI":"10.1200\/CCI.22.00185","article-title":"The feasibility, acceptability, and effectiveness of electronic patient-reported outcome symptom monitoring for immune checkpoint inhibitor toxicities: a systematic review","volume":"7","author":"Lai-Kwon","year":"2023","journal-title":"JCO Clin Cancer Inform"},{"key":"B41","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1007\/s00520-023-07934-w","article-title":"Development of an eHealth-enhanced model of care for the monitoring and management of immune-related adverse events in patients treated with immune checkpoint inhibitors","volume":"31","author":"da Silva Lopes","year":"2023","journal-title":"Support Care Cancer"},{"key":"B42","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s00520-024-09034-9","article-title":"Co-design of an electronic patient-reported outcome symptom monitoring system for immunotherapy toxicities","volume":"32","author":"Lai-Kwon","year":"2024","journal-title":"Support Care Cancer"},{"key":"B43","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1001\/jama.2022.9265","article-title":"Effect of electronic symptom monitoring on patient-reported outcomes among patients with metastatic cancer: a randomized clinical trial","volume":"327","author":"Basch","year":"2022","journal-title":"JAMA"},{"key":"B44","doi-asserted-by":"publisher","first-page":"E758","DOI":"10.1097\/NCC.0000000000000999","article-title":"Remote system for daily symptom monitoring during systemic anticancer treatment: patient acceptance, usability, and compliance","volume":"45","author":"Coolbrandt","year":"2022","journal-title":"Cancer Nurs"},{"key":"B45","doi-asserted-by":"publisher","first-page":"16212","DOI":"10.1038\/s41598-026-42768-6","article-title":"Predictors of severe immune-related adverse events during first-line immune checkpoint inhibitor therapy for advanced non-small cell lung cancer","volume":"16","author":"Olateju","year":"2026","journal-title":"Sci Rep"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1943642\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T13:08:51Z","timestamp":1788354531000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1943642\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":45,"alternative-id":["10.3389\/fmed.2026.1943642"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1943642","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]},"article-number":"1943642"}}